Bio-Techne Discloses Shareholder Lawsuit Seeking to Block Merck Vote
TECH sits 67% above its 52-week low of $43.195.
Summary
Bio-Techne disclosed a shareholder lawsuit seeking to block the September 23 vote on its $73 per share acquisition by Merck KGaA, along with voluntary supplemental proxy disclosures.
Key Events · Legal and Risk Events · TECH
-
Shareholder Lawsuit Filed
Robert Garfield v. Baumgartner et al. was filed September 9, 2026 in Minnesota state court, alleging the proxy statement misrepresented or omitted material information and seeking to enjoin the September 23 shareholder vote on the Merck KGaA merger.
-
Demand Letters Received
Multiple purported shareholders delivered demand letters alleging deficient proxy disclosures; Bio-Techne believes all allegations are without merit.
-
Supplemental Proxy Disclosures
Bio-Techne voluntarily supplemented the proxy statement with details on prior acquisition interest from Party A and Party B, Goldman Sachs engagement terms, confidentiality agreements without standstills, and additional valuation inputs including net debt figures and fully diluted share counts.
-
Vote Timeline Unchanged
The special meeting remains scheduled for September 23, 2026 at 9:00 a.m. Eastern Time; the lawsuit seeks to enjoin that vote.
Analysis · TECH · Life Sciences
A shareholder lawsuit filed September 9, 2026, alleges the proxy statement for the $73 per share Merck KGaA acquisition misrepresented or omitted material information and seeks to enjoin the September 23 shareholder vote. Bio-Techne denies the allegations but voluntarily supplemented the proxy with additional disclosures on prior acquisition interest, Goldman Sachs engagement terms, and valuation inputs. While the company believes the claims are without merit, litigation over merger proxies can delay closing or force additional disclosure, and the supplemental details provide shareholders with new information about the deal process and valuation.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.6% of the 1509 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECH was trading at $72.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.